secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-04-06T23:59:59+00:00
Accession:  0001193125-23-093153
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.01, 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics pays $14.8M to terminate Cambridge sublease with Novartis
------------------------------------------------------------------------------

- One-time termination payment of $14,780,188 to Novartis for early exit from 69,000 sq ft sublease.
- Sublease originally scheduled to end Feb 2028 or earlier; terminated effective March 31, 2023.
- Principal executive offices moving to 300 Technology Square, Cambridge, MA.
- Sublease covered R&D, laboratory, and office space at 100 Technology Square.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523093153/0001193125-23-093153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523093153/d488935d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-093153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer